PMID- 29351766
OWN - NLM
STAT- MEDLINE
DCOM- 20180918
LR  - 20181113
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 15
IP  - 1
DP  - 2018 Jan 19
TI  - Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected 
      with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis.
PG  - 19
LID - 10.1186/s12985-018-0934-6 [doi]
LID - 19
AB  - BACKGROUND: The treatment of hepatitis C virus (HCV) in HCV/human 
      immunodeficiency virus (HIV) co-infected patients remains complex. This present 
      meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment 
      in HCV/HIV co-infected patients using the most recent and available data. 
      METHODS: A systematic search of the published data was conducted in PubMed 
      Medline, EMBASE and Cochrane databases. Eligible studies were clinical trials, 
      case-control studies or prospective cohort studies aiming at assessing the 
      efficacy and safety of the SOF-containing regimens in patients co-infected with 
      HCV and HIV. Heterogeneity of results was assessed and a pooled analysis was 
      performed using random effects model with maximum likelihood estimate and 95% 
      confidence intervals (95%CI). Subgroup analysis and assessment of publication 
      bias through Egger's test were also performed. STATA 13.0 software was used to 
      analyze the data. RESULTS: Seven studies (n = 1167 co-infected patients) were 
      included in this analysis. The pooled estimate of sustained virological response 
      at 12 weeks (SVR12) was 94.0% (95%CI: 92.0%-95.0%). Subgroup analysis showed that 
      the treatment-naive patients had higher SVR12 compared with patients that were 
      treated before (chi(2) = 21.39, P < 0.01). The pooled incidence of any adverse 
      events (AEs) was 79.6% (95%CI: 77.1%-82.1%). Publication bias did not exist. 
      CONCLUSION: The results of this study showed that the treatment response of 
      SOF-containing regimens in patients co-infected with HIV and HCV was satisfied. 
      Attention should be paid to the high rates of AEs.
FAU - Li, Guotao
AU  - Li G
AD  - Department of Infectious Diseases, LuoYang Central Hospital Affiliated to 
      ZhengZhou University, Luoyang, Henan, 471000, China.
FAU - Zang, Ke
AU  - Zang K
AD  - Department of Infectious Diseases, LuoYang Central Hospital Affiliated to 
      ZhengZhou University, Luoyang, Henan, 471000, China.
FAU - Zhang, Guoqiang
AU  - Zhang G
AD  - Department of Infectious Diseases, LuoYang Central Hospital Affiliated to 
      ZhengZhou University, Luoyang, Henan, 471000, China.
FAU - Zhu, Danyan
AU  - Zhu D
AD  - Department of Infectious Diseases, LuoYang Central Hospital Affiliated to 
      ZhengZhou University, Luoyang, Henan, 471000, China.
FAU - Deng, Xiaozhao
AU  - Deng X
AUID- ORCID: 0000-0001-6995-7781
AD  - HuaDong Research Institute for Medicine and Biotecnics, No.293 Zhongshan East 
      Road, Nanjing, 210002, China. molescience@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20180119
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 0 (Antiviral Agents)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Antiviral Agents/administration & dosage/adverse effects/*therapeutic use
MH  - *Coinfection
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - HIV Infections/*drug therapy/virology
MH  - HIV-1/*drug effects/genetics
MH  - Hepacivirus/*drug effects/genetics
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Publication Bias
MH  - Sofosbuvir/administration & dosage/adverse effects/*therapeutic use
MH  - Viral Load
PMC - PMC5775578
OTO - NOTNLM
OT  - HCV/HIV co-infection
OT  - Meta-analysis
OT  - SVR12
OT  - Sofosbuvir
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR 
      PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they 
      have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral 
      with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/01/21 06:00
MHDA- 2018/09/19 06:00
PMCR- 2018/01/19
CRDT- 2018/01/21 06:00
PHST- 2017/08/09 00:00 [received]
PHST- 2018/01/15 00:00 [accepted]
PHST- 2018/01/21 06:00 [entrez]
PHST- 2018/01/21 06:00 [pubmed]
PHST- 2018/09/19 06:00 [medline]
PHST- 2018/01/19 00:00 [pmc-release]
AID - 10.1186/s12985-018-0934-6 [pii]
AID - 934 [pii]
AID - 10.1186/s12985-018-0934-6 [doi]
PST - epublish
SO  - Virol J. 2018 Jan 19;15(1):19. doi: 10.1186/s12985-018-0934-6.